GlassScriptPhysician profile
Kepeng Lu
NPI 1861856601
$7,386.28
in general payments reported to CMS, 2019-2025
43 companies · $1,523 in 2025
The $1,523 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,019 · 2022: $1,407 · 2023: $1,301 · 2024: $1,136 · 2025: $1,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,860 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,860.06 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,566.51 | 2021-2025 | Vemlidy |
| Kerecis Limited | $869.05 | 2021 | |
| Amgen INC. | $559.81 | 2021-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $469.59 | 2022-2025 | |
| Redhill Biopharma INC. | $429.79 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Novo Nordisk INC | $379.94 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $367.39 | 2021-2025 | Farxiga, Airsupra |
| Smith+Nephew, INC. | $252.84 | 2021-2022 | |
| Glaxosmithkline, LLC. | $206.96 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Esperion Therapeutics, INC. | $195.79 | 2021-2025 | Nexletol |
| Radius Health, INC. | $183.03 | 2025 | Tymlos |
| Astellas Pharma US INC | $160.76 | 2023 | Myrbetriq, Veozah |
| Biohaven Pharmaceuticals, INC. | $147.34 | 2021 | |
| Amarin Pharma, INC. | $135.66 | 2021-2022 | |
| Horizon Therapeutics Plc | $121.29 | 2022-2023 | Krystexxa |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kepeng Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.